Hansa Biopharma AB - Asset Resilience Ratio
Hansa Biopharma AB (HNSA) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2022)
This chart shows how Hansa Biopharma AB's Asset Resilience Ratio has changed over time. Check Hansa Biopharma AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Hansa Biopharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hansa Biopharma AB market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Hansa Biopharma AB maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Hansa Biopharma AB Industry Peers by Asset Resilience Ratio
Compare Hansa Biopharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Hansa Biopharma AB (2012–2022)
The table below shows the annual Asset Resilience Ratio data for Hansa Biopharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr1.69 Billion ≈ $181.59 Million |
-- |
| 2021-12-31 | 23.46% | Skr237.62 Million ≈ $25.57 Million |
Skr1.01 Billion ≈ $108.99 Million |
+6.86pp |
| 2020-12-31 | 16.60% | Skr238.14 Million ≈ $25.63 Million |
Skr1.43 Billion ≈ $154.37 Million |
-46.54pp |
| 2019-12-31 | 63.14% | Skr419.40 Million ≈ $45.13 Million |
Skr664.24 Million ≈ $71.48 Million |
+18.82pp |
| 2018-12-31 | 44.32% | Skr418.75 Million ≈ $45.06 Million |
Skr944.82 Million ≈ $101.68 Million |
+39.18pp |
| 2017-12-31 | 5.14% | Skr34.98 Million ≈ $3.76 Million |
Skr680.41 Million ≈ $73.22 Million |
-7.73pp |
| 2016-12-31 | 12.87% | Skr39.99 Million ≈ $4.30 Million |
Skr310.67 Million ≈ $33.43 Million |
+12.87pp |
| 2014-12-31 | 0.00% | Skr1.00 ≈ $0.11 |
Skr54.31 Million ≈ $5.84 Million |
+4.07pp |
| 2013-12-31 | -4.07% | Skr-2.06 Million ≈ $-222.17K |
Skr50.78 Million ≈ $5.46 Million |
-4.46pp |
| 2012-12-31 | 0.40% | Skr261.61K ≈ $28.15K |
Skr65.80 Million ≈ $7.08 Million |
-- |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more